ストックスクリーナーアプリを入手
0.8256
6.99%
-0.062
アフターアワーズ：
.82
-0.0056
-0.68%
Context Therapeutics Inc (CNTX) 最新ニュース
Context Therapeutics Inc. (NASDAQ:CNTX) Receives $6.33 Average PT from Analysts - Defense World
Context Therapeutics Grants Stock Options to New Employees - MSN
Context Therapeutics (NASDAQ:CNTX) Shares Up 2.1% – Time to Buy? - Defense World
Biotech Giant Context Therapeutics Lures Talent with Sweet Stock Rewards - Elblog.pl
Context Therapeutics Awards Buzzy Stock Options to New Talent, Poised for Tumor-Targeting Breakthroughs - Smartphone Magazine
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Context Therapeutics Strengthens Team with Strategic Equity Compensation Package - StockTitan
CNTX’s Stock Journey: What Investors Need to Know About Context Therapeutics Inc’s Performance - The InvestChronicle
Context Therapeutics to Showcase at Top 2025 Investor Conferences - MSN
Context Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Centrexion stock hits 52-week low at $0.79 amid market challenges - MSN
Centrexion stock hits 52-week low at $0.9 amid market challenges - MSN
Context Therapeutics Inc (CNTX) Stock: A SWOT Analysis - The News Heater
Mineralys Therapeutics Completes Enrollment for Explore-CKD Phase 2 Trial - MyChesCo
Context Therapeutics Inc. (NASDAQ:CNTX) Given Average Rating of "Buy" by Analysts - MarketBeat
Analysts Set Context Therapeutics Inc. (NASDAQ:CNTX) PT at $6.33 - Defense World
Context Therapeutics Stock Jumps Pre-Market On Analyst's Near 4x Upside View: Retail Pins High Hopes Too - MSN
Franklin Resources Inc. Acquires Additional Shares in Context Th - GuruFocus.com
Centrexion stock hits 52-week low at $0.9 amid market challenges By Investing.com - Investing.com South Africa
Unpacking Q3 Earnings: KLA Corporation (NASDAQ:KLAC) In The Context Of Other Semiconductor Manufacturing Stocks - Yahoo Finance
Context Therapeutics Welcomes Andy Pasternak as New Chairman of the Board - MSN
Breakthrough in Cancer Treatment? Context Therapeutics Launches Phase 1 Trial for CLDN6-Targeted Therapy - MSN
Context Therapeutics Inc. (NASDAQ:CNTX) Short Interest Update - MarketBeat
Context Therapeutics’ (CNTX) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Context doses first subject in Phase I cancer trial of CTIM-76 - Yahoo Finance
Context Therapeutics (NASDAQ:CNTX) Receives Buy Rating from D. Boral Capital - MarketBeat
Context Therapeutics Advances CTIM-76 in Clinical Pipeline - TipRanks
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76 - GlobeNewswire
Context Therapeutics Launches Phase 1 Trial for Novel Cancer Treatment CTIM-76 - StockTitan
Context Therapeutics Appoints Andy Pasternak as Chairman - TipRanks
Context Therapeutics appoints new chairman Andy Pasternak - Investing.com India
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors - The Manila Times
Context Therapeutics Names Former Horizon Executive Andy Pasternak as Board Chairman - StockTitan
Pre-market Movers: AVGR, TIVC, ATNF, SLGL... - RTTNews
Context Therapeutics Inc. (NASDAQ:CNTX) Receives $6.80 Average Target Price from Brokerages - Defense World
Geode Capital Management LLC Cuts Stock Holdings in Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
Geode Capital Management LLC Purchases 70,070 Shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
3.13%
1.23%
大文字化:
|
ボリューム (24 時間):